Literature DB >> 3104055

Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis.

S Benchekroun, B Eychenne, O Mericq, A Colombani, P Douste-Blazy, A Barret, P Sie, B Boneu.   

Abstract

In some patients affected with deep vein thrombosis (DVT) it is necessary to administer large doses of heparin to achieve proper anticoagulation. To investigate the clinical relevance of this phenomenon, we studied the heparin half-life and the heparin sensitivity after a bolus IV injection of 60 i.u. kg-1 in seven healthy volunteers and eight DVT patients investigated on day 1 or 2 and again between day 10 and 20 of the heparin therapy. The heparin half-life, the in vitro and ex vivo heparin sensitivity, were comparable in the healthy volunteers and in the patients at both times of investigation. However, there were large interindividual variations in the controls and in the patients, not correlated to the levels of any coagulation factors. Thus, the heparin hyperconsumption phenomenon occasionally observed in a given patient reflected individual characteristics and was no value in the diagnosis of DVT.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3104055     DOI: 10.1111/j.1365-2362.1986.tb02174.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

Review 1.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

2.  Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.

Authors:  Owain Thomas; Emanuel Lybeck; Karin Strandberg; Nahreen Tynngård; Ulf Schött
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.